On Monday, May 16th, the FDA issued a final guidance, entitled “Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act.” A draft of the guidance was published on August 16, 2011, and the finalized document replaces FDA’s April 2006 guidance, entitled “Guidance for Industry and FDA Staff; Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act.”
Since it was first established in 1990, section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) has undergone numerous revisions. Because of this, the guidance states that it “will assist manufacturers of devices subject to section 522 postmarket surveillance orders imposed by FDA by providing:
Section 522 of the FD&C Act grants FDA the authority to require manufacturers to conduct postmarket surveillance in various situations, including:
Manufacturers of class II and III devices that are “expected to have a significant use in pediatric populations” are required to conduct postmarket surveillance. However, FDA notes that this provision is not limited to devices labeled for pediatric use. Rather, the guidance states that “section 522(a)(1)(B) of the Act authorizes the agency to order postmarket surveillance as a condition of clearance or approval for devices expected to have significant use in pediatric populations.”
Section 522 of the FD&C Act does not define “pediatric population.” As such, the guidance document states that “FDA is defining pediatric populations to mean patients who are 21 years of age or younger at the time of diagnosis or treatment, that is, from birth through the twenty-first year of life, up to, but not including the patient’s twenty-second birthday,” which is consistent with the definition provided under section 520(m)(6)(E)(i) of the FD&C Act.
“In general, section 522(b)(1) of the Act authorizes FDA to order prospective postmarket surveillance for duration of up to 36 months unless the manufacturer and FDA agree to extend that timeframe or, if there is no agreement, after the completion of a dispute resolution as described in section 562 of the Act.” Nonetheless, the guidance states that devices expected to have significant use in pediatric populations may be subject to a surveillance period of more than 36 months. This is to assess how the device impacts growth, development, activity level, and other factors on the safety or efficacy of the device.
FDA has the authority to issue a postmarket surveillance order at the time that the device receives approval or clearance as well as anytime thereafter. The manufacturer must begin postmarket surveillance within 15 months of receiving the order.
At any point during the life cycle of a device, the FDA may identify issues that are appropriate for postmarket surveillance. These issues may be identified through:
Situations that may raise postmarket questions, during both pre and postmarket periods, include:
After the Agency has identified a potential issue with a device, the Division of Epidemiology (DEPI), Office of Surveillance and Biometrics (OSB), Center for Devices and Radiological Health (CDRH) will determine if requirements for a 522 order have been met. If they have, the Division will form a team to conduct a more in-depth review the issue. This team may be made up of FDA epidemiologists, clinicians, or other experts as needed to assess the issue. The team will review and evaluate various elements associated with the data. Upon completion of the review, the team will make a recommendation to the DEPI Division Director and OSB Director as to whether or not a 522 order should be issued.
“An order for postmarket surveillance under section 522 of the Act will generally be issued by the OSB Director. The 522 order should identify the premarket submission involved (i.e., 510(k), PMA, PDP, or HDE, or de novo petition), the public health questions, the rationale for the 522 order, and postmarket surveillance design recommendations to assist the manufacturer subject to the 522 order in preparing the postmarket surveillance plan.”
In its draft guidance, FDA provides a number of recommendations regarding the development of postmarket surveillance plans and interim and final postmarket surveillance reports.
Additional information on the Agency’s requirements is available in our FDA News article, entitled "FDA Finalizes Guidance Containing Postmarket Surveillance Recommendations, Part Two: Postmarket Surveillance Plans & Reports."
May 24, 2016
Additional information on FDA’s final guidance is available in our preceding FDA News article, entitled “FDA Finalizes Guidance Containing Postmarket Surveillance Recommendations, Part One:...
May 24, 2016
GUIDANCE DOCUMENT April 2022 This guidance is one in a series of guidance documents intended to assist industry when making certain regulatory submissions in electronic format to FDA’s Center for...
May 24, 2016
Late last month, FDA announced plans to launch a public survey to ask patients about their experiences with direct-to-consumer (DTC) drug advertisements. Background In 2002, the FDA surveyed patients...